NYSE: HQL - Tekla Life Sciences Investors

Rentabilité sur six mois: -14.59%
Rendement en dividendes: +12.12%
Secteur: Financials

Calendrier des promotions Tekla Life Sciences Investors

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Tekla Life Sciences Investors

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies.

plus de détails
It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 1992-05-04
ISIN US87911K1007
Industry Capital Markets
Sector Financials
Валюта usd
Валюта отчета usd
Див.доход ао 15.06
Дивиденд ао 2.33
Сайт https://www.teklacap.com/hql.html
Цена ао 13.01
Changement de prix par jour: -0.7704% (12.98)
Changement de prix par semaine: -1.98% (13.14)
Changement de prix par mois: -4.1% (13.43)
Changement de prix sur 3 mois: -4.59% (13.5)
Changement de prix sur six mois: -14.59% (15.08)
Changement de prix par an: -5.5% (13.63)
Evolution du prix sur 3 ans: -21.03% (16.31)
Evolution du prix sur 5 ans: -22.97% (16.72)
Evolution des prix depuis le début de l'année: -4.59% (13.5)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 4.88 3
P/BV 0.9204 9
P/E 4.96 10
EV/EBITDA 14.85 7
Total: 8.63

Efficacité

Nom Signification Grade
ROA, % 19.76 6
ROE, % 19.8 6
Total: 5.17

Dividendes

Nom Signification Grade
Div yield, % 12.12 10
DSI 0.8571 8.57
Total: 7.79

Devoir

Nom Signification Grade
Debt/EBITDA 0 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -30.15 0
Rentabilité Ebitda, % -131.71 0
Rentabilité EPS, % -41.09 0
Total: 0
Plus de détails

Plus de détails

Établissements Volume Partager, %
Saba Capital Management, L.P. 1421300 5.42
Cornerstone Advisors, LLC 494340 1.89
1607 Capital Partners, LLC 480179 1.83
Allspring Global Investments Holdings, LLC 454154 1.73
Morgan Stanley 430266 1.64
AQR Arbitrage LLC 384231 1.47
Clough Capital Partners, LP 375410 1.43
RPO LLC 338542 1.29
Needham Investment Management, L.L.C. 313792 1.2
Flagship Harbor Advisors, LLC 264003 1.01

ETFPartager, %Rentabilité pour l'année, %Dividendes, %
Saba Closed End Funds ETF 2.8917 17.31 2.29022
Amplify High Income ETF 2.263 6.94 2.77149
First Trust Income Opportunities ETF 0.4681 18.3 2.48805
1.8714.182.52



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Daniel R. Omstead M.S, Ph.D. Principal Executive Officer, President and Trustee N/A 1953 (72 année)
Mr. Peter Branner Chief Investment Officer N/A 1964 (61 année)

Adresse: United States, Boston. MA, 100 Federal Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.teklacap.com/hql.html